<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04662736</url>
  </required_header>
  <id_info>
    <org_study_id>232</org_study_id>
    <nct_id>NCT04662736</nct_id>
  </id_info>
  <brief_title>Tedizolid Suppressive Antimicrobial Therapy in a Reference Center</brief_title>
  <acronym>TediSAT</acronym>
  <official_title>Tedizolid Suppressive Antimicrobial Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the aim of the study is to describe the management and outcome of patients having an&#xD;
      osteo-articular infection treated by tedizolid as a suppressive antibiotic therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Actual">April 1, 2021</completion_date>
  <primary_completion_date type="Actual">February 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>rate of patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic therapy</measure>
    <time_frame>between 2016 and 2021</time_frame>
    <description>proportion of patients having tedizolid as a suppressive antibiotic therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>rate of failure in patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic</measure>
    <time_frame>2 years</time_frame>
    <description>proportion of patients having a failure under tedizolid as a suppressive antibiotic therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>rate of adverse event in patients having had a BJI/PJI treated with tedizolid as a suppressive</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>proportion of patients having a adverse event under tedizolid as a suppressive antibiotic therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of patients having had a BJI/PJI treated with tedizolid as a suppressive</measure>
    <time_frame>2 years</time_frame>
    <description>type of patients: age, CMI, comorbidities...</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of BJI/PJI treated with tedizolid as a suppressive</measure>
    <time_frame>2 years</time_frame>
    <description>implant or prothese or not, acute/ chronic, bacteriology</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">17</enrollment>
  <condition>Bone and Joint Infection</condition>
  <arm_group>
    <arm_group_label>patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic therapy</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic therapy</intervention_name>
    <description>description of osteo-articular infection managed with tedizolid as a suppressive antibiotic therapy</description>
    <arm_group_label>patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic therapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients having an osteo-articular infection treated with tedizolid as a suppressive&#xD;
        antibiotic therapy managed at the CRIOAc LYON, Croix-Rousse Hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients having an osteo-articular infection treated with tedizolid as a suppressive&#xD;
             antibiotic therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.crioac-lyon.fr/</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 25, 2020</study_first_submitted>
  <study_first_submitted_qc>December 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2020</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bone and joint infection</keyword>
  <keyword>tedizolid</keyword>
  <keyword>suppressive antibiotic therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Tedizolid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

